PTGXProtagonist Therapeutics, Inc.
$143.75+131% 1Y
$143.75
$64.0052 weeks$158.64
PTGX in its own filings
PTGX's filing record carries one kind of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
175
Events found in the filings · across 704 filings · the record starts in 2016
- Hard flags
- 1
Hard flags
- Most recent filing
- Aug 5, 2026
Most recent filing · Form 10-Q
- Record starts
- May 27, 2016
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 5, 2026
- Change in certifying accountanthistorical
- 2020-03-18
- Delisting notice / listing-rule failurehistorical
- 2023-07-03
- SEC comment-letter activity14 occurrences
- 2022-08-12
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 5, 2026Reports Second Quarter 2026 Financial Results and Provides Corporate Update.Earnings release · press release
- Jun 18, 2026At the Annual Meeting, the Company’s stockholders approved the adoption of the Company’s 2026 Equity Incentive Plan (the “2026 Plan”)Director or officer change · Form 8-K
- May 5, 2026Protagonist Reports First Quarter 2026 Financial.Earnings release · press release
- Feb 25, 2026Protagonist Reports Fourth Quarter and Full.Earnings release · press release
- Jan 12, 2026COMPANY OVERVIEW Dinesh V. Patel, Ph.D. President & CEO January 12, 2026.Regulation FD disclosure · press release
- Nov 6, 2025Protagonist Reports Third.Earnings release · press release
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…
On our screens:Most shorted stocks